[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601834":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":39,"collaborators":11,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":11,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":11,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":63,"whyStopped":11,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"BsAbs-treatment group","EXPERIMENTAL",null,[13],"Drug: CM336 (BCMA\u002FCD3 bispecific antibody)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","CM336 (BCMA\u002FCD3 bispecific antibody)","CM336 is a bispecific antibody targeting BCMA and CD3, designed to redirect T cells to eliminate abnormal plasma cells.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Gang An, MD","CONTACT","13502181109","angang@ihcams.ac.cn",[27],{"facility":28,"status":11,"city":29,"state":11,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":11},"Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences","Tianjin","300020","China","CN",{"type":34,"coordinates":35},"Point",[36,37],117.17667,39.14222,{"lat":37,"lon":36},{"type":40,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100601834","phase-2-bcmacd3-bsab-therapy-for-poems-syndrome-100601834",false,"NCT07115654","BCMA\u002FCD3 BsAb Therapy for POEMS Syndrome","A Prospective Single-Arm Clinical Trial of BCMA\u002FCD3 BsAb Therapy for POEMS Syndrome","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Diagnosed with POEMS syndrome according to the 2025 Chinese Expert Consensus.\n3. Deemed suitable for BCMA\u002FCD3 bispecific antibody therapy by the investigator.\n4. ECOG performance status 0-2.\n5. Adequate organ function.\n6. Provided written informed consent.\n\nExclusion Criteria:\n\n1. Not meeting the diagnostic criteria for POEMS syndrome, including:\n\n   * Chronic inflammatory demyelinating polyneuropathy (CIDP),\n   * MGUS, multiple myeloma, amyloidosis, or other plasma cell disorders not meeting POEMS diagnostic criteria.\n2. History of prior anti-plasma cell therapy, such as melphalan, cyclophosphamide, proteasome inhibitors, IMiDs, monoclonal antibodies, CAR-T, or bispecific antibodies (except:\n\n   1. Immunosuppressants used for autoimmune neuropathy;\n   2. Bisphosphonates used for bone disease;\n   3. Topical or low-dose steroids ≤20 mg\u002Fday for rheumatic disease).\n3. Investigator judges the patient unsuitable for BCMA\u002FCD3 bispecific therapy (e.g., severe cardiopulmonary dysfunction).\n4. Known allergy or intolerance to BCMA\u002FCD3 bispecific antibody or any component.","ALL","18 Years","78 Years",{"count":52,"type":53},10,"ESTIMATED","INTERVENTIONAL",[56],"PHASE2","This is a prospective, single-arm, investigator-initiated clinical trial evaluating the safety and efficacy of a BCMA\u002FCD3 bispecific antibody (CM336) in patients with POEMS syndrome.",[59],"POEMS Syndrome",[61,62],"POEMS syndrome","Bispecific antibody","NOT_YET_RECRUITING","2025-08-04",{"date":66,"type":67},"2025-08-11","ACTUAL",{"date":69,"type":53},"2025-08-10",{"date":71,"type":53},"2027-12-01",{"name":5,"class":6},1]